In keeping with this, anti-DR5 antibodies carrying the S267E (“SE”) mutation, increasing human IgG1 affinity for FcγRIIB several hundred-fold, showed improved tumor regression in mouse models humanized for FcγRIIB (109). The gene discussed is FCGR2B; the disease is neoplasm.